2021 USPSTF建议声明:阿司匹林用于预防先兆子痫及相关的发病率和死亡率

2021-09-28 美国预防医学工作组 JAMA

2021年9月,美国预防医学工作组(USPSTF)发布了阿司匹林用于预防先兆子痫及相关的发病率和死亡率的建议声明。本文是对2014年USPSTF建议声明的更新。

中文标题:

2021 USPSTF建议声明:阿司匹林用于预防先兆子痫及相关的发病率和死亡率

英文标题:

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement

发布机构:

美国预防医学工作组

发布日期:

2021-09-28

简要介绍:

2021年9月,美国预防医学工作组(USPSTF)发布了阿司匹林用于预防先兆子痫及相关的发病率和死亡率的建议声明。本文是对2014年USPSTF建议声明的更新。先兆子痫是影响孕妇最严重的健康问题之一,USPSTF专家组建议应用低剂量阿司匹林作为先兆子痫高危妊娠人群妊娠12周后先兆子痫的预防用药。

相关资料下载:
[AttachmentFileName(sort=1, fileName=jama_davidson_2021_us_210022_1631920921.26528.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1c0ee1c0022026b2, title=2021 USPSTF建议声明:阿司匹林用于预防先兆子痫及相关的发病率和死亡率, enTitle=Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement, guiderFrom=JAMA, authorId=0, author=, summary=2021年9月,美国预防医学工作组(USPSTF)发布了阿司匹林用于预防先兆子痫及相关的发病率和死亡率的建议声明。本文是对2014年USPSTF建议声明的更新。, cover=https://img.medsci.cn/20211011/1633966190184_5579292.jpg, journalId=0, articlesId=null, associationId=121, associationName=美国预防医学工作组, associationIntro=由预防和循证医学的非联邦专家和初级保健提供者(如内科,儿科医生,家庭医生,妇科/产科医生,护士和健康行为专家)组成的非联邦小组。为初级保健医生和卫生系统提供指导意见和科学证据。, copyright=0, guiderPublishedTime=Tue Sep 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年9月,美国预防医学工作组(USPSTF)发布了阿司匹林用于预防先兆子痫及相关的发病率和死亡率的建议声明。本文是对2014年USPSTF建议声明的更新。先兆子痫是影响孕妇最严重的健康问题之一,USPSTF专家组建议应用低剂量阿司匹林作为先兆子痫高危妊娠人群妊娠12周后先兆子痫的预防用药。</span></p>, tagList=[TagDto(tagId=659, tagName=阿司匹林)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=659, guiderKeyword=阿司匹林, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=107985, appHits=175, showAppHits=0, pcHits=1910, showPcHits=107806, likes=2, shares=16, comments=24, approvalStatus=1, publishedTime=Mon Oct 11 23:34:27 CST 2021, publishedTimeString=2021-09-28, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Oct 11 23:32:21 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Fri Jan 05 00:36:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=jama_davidson_2021_us_210022_1631920921.26528.pdf)])
jama_davidson_2021_us_210022_1631920921.26528.pdf
下载请点击:
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2152746, encodeId=6ac52152e4686, content=太棒啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7e8600385, createdName=ms9000001548472283, createdTime=Mon Aug 14 21:42:54 CST 2023, time=2023-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1080854, encodeId=b8ae10808547a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92e72763887, createdName=jnccgg.love, createdTime=Thu Dec 16 20:12:55 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080121, encodeId=9ccb108012134, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Tue Dec 14 23:15:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080050, encodeId=c1b5108005048, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Dec 14 20:06:29 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080027, encodeId=2dd3108002e5c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Tue Dec 14 17:52:52 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2023-08-14 ms9000001548472283 来自广东省

    太棒啦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2152746, encodeId=6ac52152e4686, content=太棒啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7e8600385, createdName=ms9000001548472283, createdTime=Mon Aug 14 21:42:54 CST 2023, time=2023-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1080854, encodeId=b8ae10808547a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92e72763887, createdName=jnccgg.love, createdTime=Thu Dec 16 20:12:55 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080121, encodeId=9ccb108012134, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Tue Dec 14 23:15:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080050, encodeId=c1b5108005048, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Dec 14 20:06:29 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080027, encodeId=2dd3108002e5c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Tue Dec 14 17:52:52 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-16 jnccgg.love

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2152746, encodeId=6ac52152e4686, content=太棒啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7e8600385, createdName=ms9000001548472283, createdTime=Mon Aug 14 21:42:54 CST 2023, time=2023-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1080854, encodeId=b8ae10808547a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92e72763887, createdName=jnccgg.love, createdTime=Thu Dec 16 20:12:55 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080121, encodeId=9ccb108012134, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Tue Dec 14 23:15:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080050, encodeId=c1b5108005048, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Dec 14 20:06:29 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080027, encodeId=2dd3108002e5c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Tue Dec 14 17:52:52 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 12cdce52m85暂无昵称

    好东西

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2152746, encodeId=6ac52152e4686, content=太棒啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7e8600385, createdName=ms9000001548472283, createdTime=Mon Aug 14 21:42:54 CST 2023, time=2023-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1080854, encodeId=b8ae10808547a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92e72763887, createdName=jnccgg.love, createdTime=Thu Dec 16 20:12:55 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080121, encodeId=9ccb108012134, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Tue Dec 14 23:15:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080050, encodeId=c1b5108005048, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Dec 14 20:06:29 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080027, encodeId=2dd3108002e5c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Tue Dec 14 17:52:52 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 ms3000001592172450

    受益匪浅!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2152746, encodeId=6ac52152e4686, content=太棒啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc7e8600385, createdName=ms9000001548472283, createdTime=Mon Aug 14 21:42:54 CST 2023, time=2023-08-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1080854, encodeId=b8ae10808547a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92e72763887, createdName=jnccgg.love, createdTime=Thu Dec 16 20:12:55 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080121, encodeId=9ccb108012134, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Tue Dec 14 23:15:21 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080050, encodeId=c1b5108005048, content=受益匪浅!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Dec 14 20:06:29 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080027, encodeId=2dd3108002e5c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Tue Dec 14 17:52:52 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 D-House

    学习

    0

拓展阅读

2010ADA/AHA/ACCF 阿司匹林对糖尿病患者心血管事件的一级预防

美国糖尿病学会(ADA,American Diabetes Association) · 2010-06-01

2014 ESC 立场声明:心血管疾病一级预防应用阿司匹林治疗

欧洲心脏病学会(ESC,European Society of Cardiology) · 2014-07-22

2014 USPSTF 小剂量阿司匹林预防孕妇先兆子痫建议声明

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2014-09-09

2016 USPSTF建议声明:阿司匹林用于心血管疾病和结直肠癌的一级预防

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2016-04-12

2015 阿司匹林用于心血管疾病一级预防的专家建议

中国心血管病相关专家小组(统称) · 2015-09-15